The FDA has sent a fresh round of warning letters to telehealth providers and compounders over claims that compounded GLP‑1 products match approved medicines, signaling intensified enforcement under agency leadership. Separately, large observational studies—one of over 600,000 U.S. veterans and another cohort analysis—reported associations between GLP‑1 receptor agonists and lower risks of substance‑use disorders and substance‑related mortality. The juxtaposition underscores growing regulatory scrutiny around how GLP‑1 therapies are marketed and compounded even as real‑world data broaden their clinical implications beyond metabolic disease. GLP‑1 receptor agonists are incretin-based agents developed for diabetes and obesity; observational findings do not prove causation and require controlled trials to confirm addiction‑related effects.